Harbour BioMed partners with Evinova China on AI-enabled drug development

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, announced a strategic collaboration in artificial intelligence (AI).

Under the terms of the collaboration, Harbour BioMed and Evinova China will jointly apply AI and digital technologies to enhance the efficiency of innovative biologics development. Building on their own strengths, the two companies aim to build an open ecosystem for AI-driven drug R&D.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, stated, “We are pleased to collaborate with Evinova to advance the application of AI in biotherapeutic development. Harbour BioMed has built a robust and differentiated product pipeline based on our industry-leading Harbour Mice® technology platform. Through this collaboration, we look forward to applying AI to improving clinical study efficiency and accelerating the delivery of innovative therapies to patients around the world.”

Nate Zhang, General Manager of Evinova China, stated, “Evinova leverages the digital transformation insights of top global pharmaceutical companies to design our AI-powered clinical development solutions and digital strategy consulting services, so that we can accelerate the delivery of better health outcomes. To realize our mission, Evinova China needs to partner with innovative companies like Harbour BioMed, which are rooted in China while harboring global ambitions. Together, through our world-class AI technology platforms and deep therapeutic expertise, we can help take China-originated breakthrough assets from the laboratory to the world.”

Collaboration Between Harbour BioMed and AstraZeneca

Evinova operates as an independent health-tech enterprise within the AstraZeneca Group, yet the relationship between Harbour BioMed and AstraZeneca extends well beyond this connection. As early as 2022, Harbour BioMed and AstraZeneca established their initial licensing partnership for HBM7022, an asset derived from the HBICE® platform. This agreement marked the first out-licensing of a bispecific antibody drug from China, laying a foundation of mutual trust between the two entities. In 2024, a second collaborative project was established through Harbour BioMed's subsidiary, Nona Biotechnology, further validating the platform's ability to consistently generate high-quality assets.

In March 2025, Harbour BioMed and AstraZeneca deepened their ties by entering into a comprehensive strategic collaboration covering multiple targets and programs. This partnership featured an innovative, multi-faceted model integrating "R&D collaboration + equity investment + establishment of a Beijing Innovation Center." On October 25, the "Harbour BioMed–AstraZeneca Innovation Lab" was officially inaugurated in Beijing, signifying a further consolidation of the partnership and accelerating the end-to-end development process for next-generation antibody drugs, from discovery through optimization.